Vanguard Group
ZVSA

Vanguard Group’s ZyVersa Therapeutics ZVSA Stock Holding History

Vanguard Group’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-49
Closed -$2.23K – 4516
2023
Q3 		$2.23K Hold
49
– – ﹤0.01% 4535
2023
Q2 		$4.22K Buy
49
+1
+2% +$262 ﹤0.01% 4545
2023
Q1 		$32.6K Buy
+48
New +$35.9K ﹤0.01% 4502

Other funds holding ZVSA

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group's ZVSA Position: Q4 2023 in Review

Vanguard Group sold out of ZyVersa Therapeutics (ZVSA) in Q4 2023, closing a stake of 49 shares — an estimated $2.23K sold.

Vanguard Group first reported a position in ZVSA in Q1 2023 and held it in 3 quarters. The position peaked at $32.6K in Q1 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q4 2023.

  • Vanguard Group reported no remaining ZyVersa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Vanguard Group sold 49 ZyVersa Therapeutics shares in Q4 2023, an estimated $2.23K.
  • Vanguard Group first reported a position in ZyVersa Therapeutics in Q1 2023 and held it in 3 quarters.
  • Vanguard Group's ZyVersa Therapeutics position peaked at $32.6K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.